COVID-19 and the Heart and VasculatureBernard Kadosh, Stuart D. Katz, Ravichandran Ramasamy et al.|Arteriosclerosis Thrombosis and Vascular Biology|2020Cited by 33
A pilot open-label study of aldose reductase inhibition with AT-001 (caficrestat) in patients hospitalized for COVID-19 infection: Results from a registry-based matched-control analysisJuan Gaztañaga, Stuart D. Katz, Ravichandran Ramasamy et al.|Diabetes & Metabolic Syndrome Clinical Research & Reviews|2021Cited by 14
A Pilot Open-label Study of Aldose Reductase Inhibition with AT-001 (caficrestat) in Patients Hospitalized for COVID-19 Infection: Results from a Registry-based Matched-control AnalysisJuan Gaztañaga, Stuart D. Katz, Riccardo Perfetti et al.|American Heart Journal|2021Cited by 1